BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21635257)

  • 1. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
    Soo GW; Law JH; Kan E; Tan SY; Lim WY; Chay G; Bukhari NI; Segarra I
    Anticancer Drugs; 2010 Aug; 21(7):695-703. PubMed ID: 20629201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
    Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
    Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
    Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ
    Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice.
    Teoh M; Narayanan P; Moo KS; Radhakrisman S; Pillappan R; Bukhari NI; Segarra I
    Pak J Pharm Sci; 2010 Jan; 23(1):35-41. PubMed ID: 20067864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
    Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.
    Chee EL; Lim AY; Modamio P; Fernandez-Lastra C; Segarra I
    Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):309-19. PubMed ID: 25656737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
    Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
    Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
    Peng B; Dutreix C; Mehring G; Hayes MJ; Ben-Am M; Seiberling M; Pokorny R; Capdeville R; Lloyd P
    J Clin Pharmacol; 2004 Feb; 44(2):158-62. PubMed ID: 14747424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.
    Lau CL; Chan ST; Selvaratanam M; Khoo HW; Lim AY; Modamio P; Mariño EL; Segarra I
    Fundam Clin Pharmacol; 2015 Aug; 29(4):404-16. PubMed ID: 26011058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
    van Erp N; Gelderblom H; van Glabbeke M; Van Oosterom A; Verweij J; Guchelaar HJ; Debiec-Rychter M; Peng B; Blay JY; Judson I
    Clin Cancer Res; 2008 Dec; 14(24):8308-13. PubMed ID: 19088049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.